Therefore, to evaluate if pharmacological inhibition of mTOR could increase sensitivity to T-DM1, we evaluated the growth inhibitory activity of T-DM1 in combination with the mTORC1 inhibitor everolimus in four HER2-positive breast cancer cell lines (Fig. S11). Here, ERBB2 is linked to breast cancer.